# EPISOME PROFILES AND MOBILIZABLE BETA-LACTAMASE PLASMID IN *HAEMOPHILUS DUCREYI*

Virapong Prachayasittikul<sup>1</sup>, Ratana Lawung<sup>2</sup> and Leif Bulow<sup>2</sup>

<sup>1</sup>Department of Clinical Microbiology, Faculty of Medical Technology, Mahidol University, Bangkok 10700, Thailand; <sup>2</sup>Department of Pure and Applied Biochemistry, Chemical Center, Lund University, Lund, S22100, Sweden

**Abstract.** Chancroid caused by *Haemophilus ducreyi* has been described as a significantly predisposing factor of HIV heterosexual transmission in an endemic region of both diseases. The fastidious, *H. ducreyi* has been reported world wide with various antimicrobial susceptibility patterns. A high tendency of drug resistances has generally been found among isolates derived in Thailand. In this study, the plasmids of *H. ducreyi* were isolated and analysed from 63 clinically derived organisms. Twenty-nine out of 63 isolates (46%) revealed the same plasmid profiles. Plasmid DNA was further cloned into *Escherichia coli* and transformants were selected. A 3.6 kb plasmid (pCb) carrying ampicillin resistance was subsequently identified. The pCb conferred resistance to various beta-lactam antibiotics including penicillin G, carbenicillin, piperacillin, cefazolin, cefoperazone, ampicillin-sulbactam, and amoxicillin-clavulanate but not to cefoxitin. Co-resistance to streptomycin, chloramphenicol and tetracycline was not detected. Beta-lactamase gene was located on the major pCb fragment of *Eco*RI and *Aat*II cutting.

## INTRODUCTION

Haemophilus ducreyi is the etiological agent of the sexually transmitted disease (STD) chancroid or soft chancre. This STD is prevalent in developing countries, especially among genital ulcerative patients (Bogaerts *et al*, 1998; Le Bacq *et al*, 1993; Taylor *et al*, 1984). Ulcerative STDs have been epidemiologically linked to the heterosexual transmission of the human immunodeficiency virus (HIV) in areas where both diseases are endemic (Jessamine and Ronald, 1990; Nelson *et al*, 1997; Wasserheit, 1992). Furthermore, individuals infected with HIV are less responsive to standard antibiotic treatment for chancroid (MacDonald *et al*, 1989; Tyndal *et al*, 1993).

Common antimicrobial agents; chloramphenicol, tetracycline, sulfonamides, kanamycin, ampicillin, and co-trimoxazole have been successfully used previously for treatment of chancroid (Hammond *et al*, 1978; Slootmans *et al*, 1987). Increasing resistance of *H. ducreyi* to antimicrobial agents has been reported from many parts of the world (Coovadia *et al*, 1985; Sng *et al*, 1982). Taylor *et al* (1985) and Rutanarugsa *et al* (1990) have reported resistance to tetracycline, sulfonamide, kanamycin, and trimethoprim of clinical *H. ducreyi* isolates have produced beta-lactamase as determined by hydrolysis of a chromogenic cephalosporin. Furthermore, it has been shown that the degree of antimicrobial resistance found in Thailand is higher than that reported for *H. ducreyi* isolates in other geographic regions (Dangor *et al*, 1990; Rutanarugsa *et al*, 1990; Taylor *et al*, 1985). Many kinds of resistance plasmids of the chancroidal agent have been reported from various parts of the world (Bilgeri *et al*, 1982; Brunton *et al*, 1979; Hansfield *et al*, 1981; Totten *et al*, 1982). In this report we have classified the clinical isolates of *H. ducreyi* by determining extra-chromosomal DNA profiles and partially characterizing the mobilizable ampicillin resistance plasmid in *H. ducreyi*.

## MATERIALS AND METHODS

# **Bacterial strains**

*Haemophilus ducreyi* isolates were collected from chancroid patients during 1982-1983 (31 isolates) and 1989-1990 (32 isolates). They were stored in 10% skimmed milk with 20% glycerol and 5% fetal bovine serum at -80°C. They were cultured for 48 hours on chocolate agar (Gonococcal base medium supplemented with 2% bovine hemoglobin and 1% isovitalex). The medium was incubated at 33°C in a candle jar and moisture.

## **Beta-lactamase production**

The production of beta-lactamase was detected

Correspondence: Virapong Prachayasittikul, Department of Clinical Microbiology, Faculty of Medical Technology, Mahidol University, Bangkok 10700, Thailand.

using the chromogenic cephalosporin (nitrocefin, Oxoid) substrate. Penicillinase producing *Neisseria* gonorrhoeae (PPNG) and non PPNG were used as controls.

## **Preparation of plasmids**

Plasmids were prepared by two methods depending on the bacterial species. Plasmids of E. coli transformants were extracted using a QIAprep Spin Miniprep kit<sup>™</sup> (QIAGEN). H. ducreyi plasmids were isolated according to Meyers et al (1976). H. ducreyi cells were harvested, washed and suspended in 25% sucrose in Tris-EDTA pH 8.0 containing 5 mg/ml lysozyme. The mixture was then gently lysed with 1/3 volume of 0.25 M EDTA pH 8.0 and 10% SDS (final concentration 1%). To the viscous solution, 5 M NaCl was added to give a final concentration of 1 M and placed at 4°C overnight. The suspension was then centrifuged at 10,000g for 30 minutes. Suspended DNA was treated with RNaseA (final concentration 25 mg/l) and further purified by phenol/chloroform extraction. DNA was analyzed on 0.7% agarose gel electrophoresis.

#### Transformation

*Escherichia coli* strain TG1 was cultivated in LB medium and transformed using the conventional calcium chloride method (Sambrook *et al*, 1990).

#### Susceptibility test

Antimicrobial susceptibility was tested using a disc diffusion method for the *E. coli* transformants (Lorian, 1991). The obtained ampicillin resistant transformants were tested against many kinds of beta-lactam antibiotics (Difco); cefazolin (30 µg), cefoperazone (75  $\mu$ g), piperacillin (100  $\mu$ g), carbenicillin (100  $\mu$ g), cefoxitin (30  $\mu$ g), ampicillinsulbactam (10  $\mu$ g/10  $\mu$ g), amoxicillin-clavulanate (20  $\mu$ g/10  $\mu$ g), respectively. Moreover, they were also tested against other groups of antibiotics; chloramphenicol (30  $\mu$ g), tetracycline (30  $\mu$ g), and streptomycin (10  $\mu$ g).

#### RESULTS

We followed the method of Meyers et al (1976) to isolate H. ducreyi plasmids. All 63 clinically derived H. ducreyi isolates carried at least three kinds of plasmids, and plasmids from individual organisms could be classified into seven plasmid patterns (Table1, Fig 1). The 3.6 and 7.1 kb plasmids were found in all H. ducreyi isolates. Pattern VI was the most prevalent (46%). However, disparity of plasmid pattern carrying between isolates collected during 1982-1983 and 1989-1990 was observed (Table 2). During 1989-1990, only patterns I, III, V, VI were found with the frequency of 3.1%, 43.8%, 3.1%, and 50%, respectively. During 1982-1983, all patterns were found with the frequency of 12.9% (Pattern I), 6.5% (Pattern II), 12.9% (Pattern III), 19.4% (Pattern IV), 3.2% (Pattern V), 41.9% (Pattern VI), and 3.2% (Pattern VII). More importantly, all seven patterns remained their unique self-individual patterns after digestion with restriction enzymes. With the three endonucleases (HindIII, PstI, and EcoRI), classification of the seven plasmid patterns remained the same (data not shown).

Mobilized plasmids of *H. ducreyi* plasmid pattern VI could be transferred by artificial transformation and expressed in *E. coli* transformants.

Pattern	Plasmid size (kb)*	No. of isolates(%) (n=63)
Ι	3.6, 4.3, 7.1, 9.6	5(7.9)
II	3.6, 4.3, 6.2, 7.1, 9.6	2(3.2)
III	3.6, 4.3, 7.1, 8.7, 9.6, >23.1	18(28.6)
IV	3.6, 4.3, 7.1, 9.6, 10.7, >23.1	6(9.5)
V	3.6, 7.1, 8.7	2(3.2)
VI	2.1, 3.2, 3.6, 4.3, 6.2, 7.1, 9.6	29(46.0)
VII	3.6, 4.3, 6.2, 7.1, 8.7, 9.6, 10.7, >23.1	1(1.6)

Table 1 Plasmid patterns found in clinical *H. ducrevi* isolates.

\* Size of plasmids were compared to  $\lambda$  HindIII fragments.

Table 2
Prevalence of Haemophilus ducreyi carrying
plasmid patterns during 1982-1983 and 1989-
1990.

	No. of isolates(%)		
Plasmid pattern	1982-1983 (n=31)	1989-1990 (n=32)	
Ι	4(12.9)	1(3.1)	
II	2(6.5)	0(0)	
III	4(12.9)	14(43.8)*	
IV	6(19.4)*	0(0)	
V	1(3.2)	1(3.1)	
VI	13(41.9)	16(50.0)	
VII	1 (3.2)	0(0)	

\*Denote significant difference between the two time periods.

These plasmids could be successfully maintained in the E. coli host under ampicillin selective pressure. The ampicillin resistance transformants produced beta-lactamase enzymes which were secreted into the medium. The transformants were susceptible to cefoxitin, but were resistant to many other kinds of beta-lactam antibiotics including cefazolin, cefoperaxone, piperacillin, carbenicillin, ampicillin-sulbactam, and amoxicillin-clavulanate, respectively. However, they were susceptible to other groups of antibiotics such as chloramphenicol and streptomycin. They were found to possess the 3.6 kb plasmid (pCb). This plasmid could not be digested by NsiI, NotI, SacI, and SmaI restriction enzymes while provided certain site for abundance of restriction endonuclease (Fig 2). We found that ampicillin resistance gene is located on the major fragment of pCb after digestion with EcoRI and AatII.

#### DISCUSSION

The fastidious *H. ducreyi* has been reported world wide with various antimicrobial susceptibility patterns (Coovadia *et al*, 1985; Sng *et al*, 1982). Plasmids of similar molecular weights have been identified from epidemiologically linked cases and plasmids of different molecular weight have been found in isolates from different geographic areas (Bilgeri *et al*, 1982; Brunton *et al*, 1979; Hansfield *et al*, 1981; Totten *et al*, 1982). Resistance plasmids of the chancroidal agent have been reported




Fig 1–Plasmid profiles of clinical *H. ducreyi* isolates: Lane 1, 2, 3, 4, 5, 6, and 7 represented the plasmid pattern I, II, III, IV, V, VI, and VII, respectively, as classified from 63 *H. ducreyi* isolates. Lane M is  $\lambda$  *Hin*dIII fragments as molecular weight markers.




Fig 2–Restriction enzymes map of pCb ampicillin resistance plasmid.

from many parts of the world. We found that every single isolate of *H. ducreyi* carried at least three plasmids. Such plasmids may be cryptic, carry the unreveal function or carry drug resistance characteristics. Using plasmid sizes as criterion of cell classification we could subtype the *H. ducreyi* into seven plasmid profile types (Table 1). More-

over, disparity of plasmid patterns carrying between isolates collected during 1982-1983 and isolates collected during 1989-1990 suggested a mobility in plasmid compositions (Table 2). Our results are also similar to those previously described by Sarafian et al (1991). They found that 29 out of 30 H. ducreyi isolates possessed at least three plasmids, as determined by the distribution of molecular mass observed. Possible eight plasmids, ranging in size from about 1.8 to 10 Mda, were observed. The frequency of plasmids found in Thailand is much higher as compared with other regions. The isolates from Thailand appear to be unique; the number and diversity of the plasmids present in each of these isolates distinguish them from strains previously isolate in United States, Canada, or Kenya (MacNicol and Ronald, 1985). In the United States, Sarafian and Knapp (1992) has reported that 30% of H. ducreyi isolates possessed no plasmid, and 64% possessed one plasmid and only 1 out of 342 isolates from a patient in San Francisco, California, possessed 4 plasmids. This also indicates the potential of plasmid pattern as a molecular epidemiological tool. Although, it has been suggested that the molecular weight plasmid profile is not the epidemiological marker of strain identity (Handsfield et al, 1981; Totten et al, 1982). However, plasmid profiles are widely accepted and used as simple epidemiological marker in many kinds of bacterial infections (Olsen et al, 1992).

Mobilization of extrachromosomal DNA, particular R plasmid of H. ducreyi, to other gram negative bacteria has previously been reported (Brunton et al, 1986). Deneer et al (1982) have demonstrated an African H. ducrevi isolate containing three plasmids; a 10.6 kb ampicillin resistance plasmid, a 7.4 kb sulfonamide resistance plasmid, and a 35.6 kb phenotypically cryptic plasmid. In natural event of genes transforming the 35.6 kb can mediate the transfer of non-conjugative 10.6 kb ampicillin resistance gene to the recipient bacteria by transconjugation. Transfering of beta-lactamase gene to H. parainfluenzae and N. gonorrhoeae have been reported (Brunton et al, 1986; MacNicol et al, 1986). Variant ampicillin resistance plasmids have been reported from many geographic regions; the 10.6 kb, the 8.6 kb which is prevalence in African isolates, the 4.8 kb which is prevalence in US and Canada isolates, the 5.4 kb, the 3.9 kb which is reported from Thailand (Brunton et al, 1979; Handsfield et al, 1981; Maclean et al, 1992; MacNicol and Ronald, 1985; Sarafian et al, 1991; Totten et al, 1982). Our artificial gene

transfer of *H. ducreyi* plasmids to *E. coli* revealed the 3.6 kb ampicillin resistance plasmid which is digested by many restriction endonucleases. This plasmid may be identical to the 3.9 kb plasmid that was described by Sarafian *et al* (1991). However, the ampicillin resistance transformants of *E. coli* were not obtained when the donor DNA contained the 3.9 kb plasmid. It will be interesting to further classify and characterize the beta-lactamase enzyme which is produced by the ampicillin resistance transformant of *E. coli* carrying the 3.6 kb plasmid.

# REFERENCES

- Bilgeri YR, Bullard RC, Duncan MD, Mauff AC, Koornhof HJ. Antimicrobial susceptibility of 103 strains of *Haemophilus ducreyi* isolated in Johannesburg. *Antimicrob Agents Chemother* 1982; 22:686-8.
- Bogaerts J, Karstens L, Van Dyck E, Tello WM, Akingeneye J, Mukantabana V. Genital ulcers in a primary health clinic in Rwanda: impact of HIV infection on diagnosis and ulcer healing (1986-1992). Int J STD AIDS 1998; 9: 706-10.
- Brunton JL, MacLean IW, Ronald AR, Albritton WL. Plasmid-mediated ampicillin resistance in *Haemophilus ducreyi*. *Antimicrob Agents Chemother* 1979; 15:294-9.
- Brunton J, Meier M, Erhman N, Clare D, Almawy R. Origin of small β-lactamase-specifying plasmids in Haemophilus species and *Neisseria gonorrhoeae*. *J Bacteriol* 1986; 168:374-9.
- Coovadia YM, Kharsany A, Hoosen A. The microbial aetiology of genital ulcers in black men in Durban, South Africa. *Genitourin Med* 1985; 61:266-9.
- Dangor Y, Ballard RC, Miller SD, Koornhof HJ. Treatment of chancroid. Antimicrob Agents Chemother 1990; 34:1308-11.
- Deneer HG, Sleney L, Maclean IW, Albritton WL. Mobilization of nonconjugative antibiotic resistance plasmids in *Haemophilus ducreyi*. J Bacteriol 1982; 149:726-32.
- Hammond GW., Lian CJ, Wilt JC, Ronald AR. Antimicrobial susceptibility of *Haemophilus ducreyi*. Antimicrob Agents Chemother 1978; 13:608-612.
- Handsfield HH, Totten PA, Fennel CL, Falkow S, Holmes KK. Molecular epidemiology of *Haemophilus ducreyi* infections. *Ann Intern Med* 1981; 95:315-8.
- Jessamine PG, Ronald AR. Chancroid and the role of genital ulcer disease in the spread of human retroviruses. *Med Clin North Am* 1990; 74: 1417-1431.

- Le Bacq F, Mason PR, Gwanzura L, Robertson VJ, Latif AS. HIV and other sexually transmitted diseases at a rural hospital in Zimbabwe. *Genitourin Med* 1993; 69: 352-6.
- Lorian V. Antibiotics in laboratory medicine, 3<sup>rd</sup> ed. Baltimore: Williams and Wilkins 1991.
- MacDonald KS, Cameron DW, D'Costa L, Ndinya-Achola JO, Plummer FA, Ronald AR. Evaluation of fleroxacin (RO 23-6240) as single-oral-dose therapy of culture-proven chancroid in Nairobi, Kenya. Antimicrob Agents Chemother 1989; 33:612-4.
- Maclean IW, Slaney L, Inteau JM, Levesque RC, Albritton WL, Ronald AR. Identification of a ROB-1 betalactamase in *Haemophilus ducreyi*. *Antimicrob Agents Chemother* 1992; 36:467-9.
- MacNicol PJ, Ronald AR. The plasmids of Haemophilus ducreyi. J Antimicrob Chemother 1985; 14:561-4.
- MacNicol PJ, Albritton WL, Ronald AR. Transfer of plasmid- mediated ampicillin resistance from *Haemophilus* to *Neisseria gonorrhoeae* requires an interventing organism. *Sex Transm Dis* 1986; 13:145-50.
- Meyers JA, Sanchez D, Elwell LP, Falkow S. Simple agarose gel electrophoretic method for the identification and characterization of deoxyribonucleic acid. *J Bacteriol* 1976; 127:1529-37.
- Nelson KE, Eiumtrakul S, Celentano D, et al. The association of herpes simplex virus type 2 (HSV-2), Haemophilus ducreyi, and syphilis with HIV infection in young men in northern Thailand. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16: 293-300.
- Olsen JE, Sorensen M, Brown DJ, Gaaroslev K, Bisgaard M. Plasmid profiles as an epidemiological marker in Salmonella enterca serovar berta infections. Acta Pathol Microbiol Scand 1992; 100:221-8.
- Rutanarugsa A, Vorachit M, Polnikorn N, Jayanetra P. Drug resistance of *Haemophilus ducreyi*. Southeast Asian J Trop Med Public Health 1990; 21:185-93.

- Sambrook J, Fritsch EF, Maniatis T. Molecular cloning. A laboratory manual. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press. 1989.
- Sarafian SK, Johnson SR, Thomas ML, Knapp JS. Novel plasmid combinations in *Haemophilus ducreyi* isolates from Thailand. *J Clin Microbiol* 1991; 29:2303-4.
- Sarafian S, Knapp. Molecular epidemiology, based on plasmid profiles of *Haemophilus ducreyi* infections in the United States: Results of surveillance, 1981-1990. Sex Transm Dis 1992; 19:35-8.
- Slootmans L, Vanden Berghe DA, Van Dyck E, Piot P. Susceptibility patterns of fifty-seven strains of *Haemophilus ducreyi* isolated in Amsterdam from 1978 to 1985. *J Antimicrob Chemother* 1987; 19:187-91.
- Sng EH, Lim AL, Rajan VS, Goh AJ. Characteristics of *Haemophilus ducreyi*. A study. Br J Vener Dis 1982; 58:239-42.
- Taylor DN, Duangmani C, Suvongse C, et al. The role of Haemophilus ducreyi in penile ulcers in Bangkok, Thailand. Sex Transm Dis 1984; 11:148-51.
- Taylor DN, Escheverria P, Hanchalay S, Pitarangsi C, Slootmans L, Piot P. Antimicrobial susceptibility and characterization of outer membrane proteins of *Haemophilus ducreyi* isolated in Thailand. J Clin Microbiol 1985; 21:442-4.
- Totten PA, Handsfield HH, Peters D, Holmes KK, Falkow S. Characterization of ampicillin resistance plasmids from *Haemophilus ducreyi*. Antimicrob Agents Chemother 1982; 21:622-7.
- Tyndal MW, Plourde PJ, Agoki E, *et al.* Fleroxacin in the treatment of chancroid an open study in men seropositive or sero-negative for the human immunodeficiency virus type 1. *Am J Med* 1993; 94:85S-8S.
- Wasserheit JN. Epidemiological synergy interrelationships between human immunodeficiency virus infection and other sexually transmitted diseases. Sex Transm Dis 1992; 19:61-77.